Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
Public ClinicalTrials.gov record NCT05600114. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study, Evaluating the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution in Subjects With Social Anxiety Disorder
Study identification
- NCT ID
- NCT05600114
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- EmpowerPharm Inc.
- Industry
- Enrollment
- 239 participants
Conditions and interventions
Conditions
Interventions
- Cannabidiol oral solution Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 26, 2022
- Primary completion
- Dec 12, 2023
- Completion
- Dec 12, 2023
- Last update posted
- Nov 20, 2024
2022 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 8
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| EPI-CBD-001 Site | Encino | California | 91316 | — |
| EPI-CBD-001 Site | Lemon Grove | California | 91945 | — |
| EPI-CBD-001 Site | Los Alamitos | California | 90720 | — |
| EPI-CBD-001-Site | Oceanside | California | 92056 | — |
| EPI-CBD-001 site | San Jose | California | 95124 | — |
| EPI-CBD-001 Site | Jacksonville | Florida | 32256 | — |
| EPI-CBD-001 Site | Lauderhill | Florida | 33319 | — |
| EPI-CBD-001 Site | Maitland | Florida | 32751 | — |
| EPI-CBD-001 Site | Orlando | Florida | 32801 | — |
| EPI-CBD-001 Site | Chicago | Illinois | 60640 | — |
| EPI-CBD-001 Site | Cedarhurst | New York | 11516 | — |
| EPI-CBD-001-Site | New York | New York | 10036 | — |
| EPI-CBD-001-Site | Rochester | New York | 10036 | — |
| EPI-CBD-001 Site | Oklahoma City | Oklahoma | 73106 | — |
| EPI-CBD-001 Site | Portland | Oregon | 97210 | — |
| EPI-CBD-001 site | Wichita Falls | Texas | 76309 | — |
| EPI-CBD-001 Site | Bellevue | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05600114, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2024 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05600114 live on ClinicalTrials.gov.